Pravin T P Kaumaya

US Patent:

8080253, Dec 20, 2011

Filed:

Feb 7, 2005

Appl. No.:

11/052721

Inventors:

Pravin Kaumaya - Westerville OH, US
David Cohn - Bexley OH, US

Assignee:

The Ohio State University Research Foundation - Columbus OH

International Classification:

A61K 39/00
A61K 38/18
C07H 21/04

US Classification:

4241921, 4241841, 4241851, 514 81, 536 234

Abstract:

Compositions for and methods of treating patients with malignancies associated with overexpression of VEGF, particularly ovarian cancer are provided herein. The compositions include but are not limited to certain VEGF epitopes, multivalent peptides comprising the epitopes, and chimeric peptides comprising one or more of the epitopes and a T cell epitope.

US Patent:

8110657, Feb 7, 2012

Filed:

Jan 6, 2010

Appl. No.:

12/683114

Inventors:

Pravin Kaumaya - Westerville OH, US

Assignee:

The Ohio State University - Columbus OH

International Classification:

A61K 38/00

US Classification:

530326, 530300, 530350, 514 2, 514 13, 4241851, 4242771

Abstract:

Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided.

US Patent:

8470333, Jun 25, 2013

Filed:

Feb 1, 2010

Appl. No.:

12/697578

Inventors:

Pravin Kaumaya - Westerville OH, US

Assignee:

The Ohio State University Research Foundation - Columbus OH

International Classification:

A61K 39/00

US Classification:

4241921, 4241851, 4241941, 514 2, 530300

Abstract:

Compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include epitopes of the HER-2 proteins.

US Patent:

20020156008, Oct 24, 2002

Filed:

Nov 21, 2001

Appl. No.:

09/990574

Inventors:

Pravin Kaumaya - Westerville OH, US
Caroline Whitacre - Columbus OH, US

International Classification:

A61K038/10
A61K038/16
C07K007/08

US Classification:

514/012000, 514/013000, 514/014000, 530/324000, 530/326000

Abstract:

Agents for blocking T cell-mediated immune reactions are provided. Such agents are peptides, referred to hereinafter as “CD28 peptide mimetics”, of from 15 to 30 amino acids in length. The CD28 peptide mimetics comprise the hexapeptide motif ‘MYPPPY’ or a retro-inverso isomer thereof. The CD 28 peptide mimetics further comprise flanking sequence at the amino and carboxyl terminus of the hexapeptide motif. Such flanking sequence permit the CD28 peptide mimetic to assume a polyproline II (PPII) conformation when placed in water or a buffered solution at physiological pH and a temperature of about 25 C. Methods for treating subjects with T cell mediated autoimmune diseases or disorders are also provided Such methods comprise administering one or more of the CD 28 peptide mimetics to a subject which has such disease or disorder 30. The present invention also relates to a method of blocking activation and proliferation of CD4+ cells. The method comprises contacting such cells with one or more of the present CD 28 peptide mimetics.

US Patent:

20030113344, Jun 19, 2003

Filed:

Aug 19, 2002

Appl. No.:

10/223711

Inventors:

Lauren Bakaletz - Columbus OH, US
Pravin Kaumaya - Westerville OH, US

International Classification:

A61K039/385
C07K014/195

US Classification:

424/194100, 530/350000

Abstract:

The present invention provides synthetic chimeric fimbrin peptides which induce an immunogenic response in animals to non-typable Haemophilus influenzae and that do not require tedious purification techniques. The synthetic chimeric fimbrin peptides reduce the severity of otitis media caused by Haemophilus influenzae. The synthetic chimeric fimbrin peptides are synthesized using commercially available peptide synthesizers. The synthetic chimeric fimbrin peptides comprises three peptide units. The first peptide unit is a subunit of the fimbrin protein. Preferably, the fimbrin subunit is comprised of the amino acids of Sequence ID No. 1 or Sequence ID No. 2. The second peptide unit is a t cell epitope, and preferably has the amino acid sequence of SEQ ID NO. 3. The third peptide unit is a linker peptide unit which joins the first and second peptide unit. The linking sequence preferably has from about 2 to about 15 amino acids, more preferably from about 2 to about 10 amino acids, most preferably from about 5 to about 6 amino acids. The synthetic chimeric fimbrin peptides are useful immunognes against NTHi and also useful as laboratory tool for detecting antibodies in sera. The invention also relates to an immunogenic composition conmtaining the synthetic chimeric fimbrin peptides and a pharmacologically acceptable carrier.

US Patent:

20070060516, Mar 15, 2007

Filed:

Jun 15, 2006

Appl. No.:

11/424526

Inventors:

Pravin Kaumaya - Westerville OH, US
Joan Steele - Columbus OH, US
Stephanie Allen - Hilliard OH, US

Assignee:

The Ohio State University Research Foundation - Columbus OH

International Classification:

A61K 38/16
A61K 38/10

US Classification:

514012000, 514013000, 514014000, 530324000, 530325000, 530326000

Abstract:

Compositions, methods, and vaccines that may stimulate the immune system and that may be used for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include epitopes of the HER-2 proteins.

US Patent:

20070071827, Mar 29, 2007

Filed:

Jun 9, 2006

Appl. No.:

11/423194

Inventors:

Pravin Kaumaya - Westerville OH, US
Vernon Stevens - Dublin OH, US
Pierre Triozzi - Columbus OH, US

Assignee:

THE OHIO STATE UNIVERSITY - Columbus OH

International Classification:

A61K 38/17
A61K 38/10
C07H 21/04
A61K 9/14

US Classification:

424489000, 514012000, 514013000, 514014000, 977906000, 536023500

Abstract:

Compositions for stimulating the immune system and for treating malignancies associated with overexpression of the HER-2 protein are provided. Such compositions include immunogenic epitopes of the HER-2 proteins and chimeric and multivalent peptides which comprise such epitopes. The present invention also relates to polynucleotides which encode the chimeric peptides. Also provided are pharmaceutical compositions comprising such immunogenic compositions. Methods for stimulating an immune response to HER-2 protein are provided. Methods for treating breast cancer, ovarian cancer, prostate cancer, colon cancer and lung cancer are provided.

US Patent:

20070243206, Oct 18, 2007

Filed:

May 7, 2007

Appl. No.:

11/745177

Inventors:

Lauren Bakaletz - Hilliard OH, US
Pravin Kaumaya - Westerville OH, US

Assignee:

The Ohio State University - Columbus OH

International Classification:

A61K 39/02
A61K 39/00

US Classification:

424190100, 424185100

Abstract:

The present invention provides synthetic chimeric fimbrin peptides which induce an immunogenic response in animals to non-typable and that do not require tedious purification techniques. The synthetic chimeric fimbrin peptides reduce the severity of otitis media caused by The synthetic chimeric fimbrin peptides are synthesized using commercially available peptide synthesizers. The synthetic chimeric fimbrin peptides comprises three peptide units. The first peptide unit is a subunit of the fimbrin protein. Preferably, the fimbrin subunit is comprised of the amino acids of Sequence ID No. 1 or Sequence ID No. 2. The second peptide unit is a t cell epitope, and preferably has the amino acid sequence of SEQ ID NO. 3. The third peptide unit is a linker peptide unit which joins the first and second peptide unit. The linking sequence preferably has from about 2 to about 15 amino acids, more preferably from about 2 to about 10 amino acids, most preferably from about 5 to about 6 amino acids. The synthetic chimeric fimbrin peptides are useful immunogens against NTHi and also useful as laboratory tool for detecting antibodies in sera. The invention also relates to an immunogenic composition containing the synthetic chimeric fimbrin peptides and a pharmacologically acceptable carrier.